Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling

Clinical Cancer Research

Volumn 14, Issue 21, 2008, Pages 6907-6915

  Roué, Gael ^a   López Guerra, Mónica ^a   Milpied, Pierre ^a   Pérez Galán, Patricia ^a   Villamor, Neus ^a   Montserrat, Emili ^a   Campo, Elias ^a   Colomer, Dolors ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CASPASE; FLUDARABINE; GEMCITABINE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ALKYLATING AGENT; CHLORMETHINE DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MANTLE CELL LYMPHOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; APOPTOSIS; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CASPASES; FEMALE; GENES, P53; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MUTATION; NITROGEN MUSTARD COMPOUNDS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 58149214372     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0388     Document Type: Article

References (40)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-15.
2. Binet JL, Caligaris-Cappio F, Catovsky D, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006;107:859-61.
3. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-62.
4. Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005;23:6409-14.
5. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004;23:2785-96.
6. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37.
7. Koduru PR, Raju K, Vadmal V, et al. Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997;90:4078-91.
8. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002;29:4-11.
9. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309-17.
10. Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287-8.
11. Schmidt-Hieber M, Schmittel A, Thiel E, Keilholz U. A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma. Melanoma Res 2004;14:439-42.
12. von MG, Chernozemsky I, Sirakova L, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005;16:871-7.
13. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005;90:1357-64.
14. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204-10.
15. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383-9.
16. Camps J, Salaverria I, Garcia MJ, et al. Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res 2006;30:923-34.
17. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 2002;100:1810-6.
18. Roue G, Perez-Galan P, Lopez-Guerra M, et al. Selective inhibition of IκB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 2007;178:1923-30.
19. Schwanen C, Hecker T, Hubinger G, et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002;16:2096-105.
20. Ferrer A, Marce S, Bellosillo B, et al. Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. Oncogene 2004;23:8941-9.
21. Marce S, Molina-Arcas M, Villamor N, et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 2006;91:895-902.
22. Bottke D, Bathe K, Wiegel T, Hinkelbein W. Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol 2007;183:128-32.
23. Rummel MJ, Mitrou PS, Hoelzer D. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Semin Oncol 2002;29:27-32.
24. Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007;59:759-70.
25. Erlacher M, Labi V, Manzl C, et al. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J Exp Med 2006;203:2939-51.
26. Perez-Galan P, Roue G, Villamor N, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-64.
27. Vousden KH. Apoptosis. p53 and PUMA: a deadly duo. Science 2005;309:1685-6.
28. Fernandez Y, Verhaegen M, Miller TP, et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005;65:6294-304.
29. Qin JZ, Ziffra J, Stennett L, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005;65:6282-93.
30. Armstrong JL, Veal GJ, Redfern CP, Lovat PE. Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours. Apoptosis 2007;12:613-22.
31. Li GX, Hu H, Jiang C, Schuster T, Lu J. Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int J Cancer 2007;120:2034-43.
32. May MJ, Madge LA. Caspase inhibition sensitizes inhibitor of NF-κB kinase β-deficient fibroblasts to caspase-independent cell death via the generation of reactive oxygen species. J Biol Chem 2007;282:16105-16.
33. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006;12:440-50.
34. 2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-25A and ATM-p53-21-pathways. J Cancer Res Clin Oncol 2008;134:245-53.
35. Moubarak RS, Yuste VJ, Artus C, et al. Sequential activation of poly(ADP-ribose) polymerase 1, calpains, and Bax is essential in apoptosis-inducing factor-mediated programmed necrosis. Mol Cell Biol 2007;27:4844-62.
36. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 2005;11:3155-62.
37. Feng L, Achanta G, Pelicano H, et al. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int J Mol Med 2000;5:597-604.
38. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006;132:105-12.
39. Koppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone - a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leuk Lymphoma 2004;45:911-3.
40. Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007;48:1299-306.